The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) will review data on medicines containing pseudoephedrine hydrochloride following reports that the decongestant drugs are associated with two potentially serious vasoconstrictive brain conditions.
Source: Drug Industry Daily